Compound
← Compound
Official website →
CORCencora, Inc.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- COR
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-09-30
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable…
IndustryMedical - Distribution
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
22.84×
P/B
Price divided by book value
19.55×
EV/EBITDA
Enterprise value divided by operating cash generation
13.44×
EV/Revenue
Enterprise value divided by revenue
0.21×
What the company earns
ROE
Return on shareholders’ equity
106.4%
ROA
Return on all assets
3.1%
Gross margin
What remains after product costs
3.7%
Operating margin
What remains after operating the business
1.3%
Net margin
How much of each revenue unit becomes profit
0.8%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
3.84
Total debt
Sum of borrowings
$11.72B
Cash
Cash available to cover it
$2.82B
Current ratio
Short-term assets divided by short-term liabilities
0.93
Free cash flow
Cash left after investing
$2.43B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.57
Revenue growth
Compared with the same period a year earlier
5.1%
Earnings growth
Compared with the same period a year earlier
11.1%
Dividend yield
Trailing 12-month distributions divided by price
0.8%
Market data provider figures for the latest published period. Informational, not investment advice.
What research firms say
Buy 33Hold 12Sell 1· 46 firms
Published targetsrange 30% from lowest to highest
330.00median 350.00 USD430.00
Recent revisions
RBC CapitalSector Perform
Wells FargoOverweight
JP MorganOverweight
Research-firm survey compiled by StreetInsider, Benzinga, Pulse 2.0. This is not Compound analysis or investment advice — Compound does not issue price targets.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 238.59B | 262.17B | 293.96B | 321.33B |
| Custo dos produtos | -230.29B | -253.21B | -284.05B | -309.85B |
| Lucro bruto | 8.3B | 8.96B | 9.91B | 11.48B |
| Despesas com vendas e administrativas | -4.85B |
News about COR
Yahoo Finance · yesterday
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Yahoo Finance · 2 days ago
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?
Yahoo Finance · 12 days ago
Is Cencora Stock Underperforming the Dow?
Follow COR and get agent analysis of what is moving the stock.
Open Compound